03/08/2020 - General information
The Innovation Radar, a European Commission initiative to identify high potential innovations and innovators in EU-funded research and innovation framework programmes, has selected two innovations developed by the GRIB in the project eTRANSAFE to be included on the Innovation Radar platform: Preclinical text mining solution for treatment response Advanced in silico modelling to predict toxicity These innovations, stemming from the project work, have been classified by the Innovation Radar as Exploring innovations in the early phases of technological readiness and have been published on the EU-funded innovations website on July 20th 2020, thus joining the 3600+ EU-funded innovations already showcased on the platform.
30/06/2020 - General information
The successful projects are "Obtaining antioxidant active substances from the carob pod and validating their therapeutic potential", which involves the company Euronutra, the IBIMA (Malaga Biomedical Research Institute), the IMIM (Hospital del Mar Medical Research Institute), and the CRG (Centre for Genomic Regulation); and the project "Development of a new therapy for Fragile X syndrome", in which the company Connecta Therapeutics, the IMIM, and the CRG are participating. The Spanish Innovation Agency call for these grants is part of the State Plan for Scientific and Technical Research and Innovation 2017-2020. The goal is to finance cooperative projects between companies and research bodies in order to carry out joint R&D projects that are close to the market and that, due to their subject matter, are aligned with the priorities established in the challenges of the State R&D Programme Oriented to the Challenges of Society. This year's call has a budget of 260 million euros and one of the requirements is that the coordinator applying for the grant must be a company.
29/06/2020 - General information
This month Sifted, the technology magazine of the Financial Times, has contacted various experts in the technology industry and in analyzing data on investments, has concluded that the Spanish entrepreneurial ecosystem has high quality healthtech startups, ranging from drug discovery to novel virtual reality therapies. In its latest edition, Sifted has published a list of the top healthcare start-ups in Spain, including Chemotargets, the IMIM's spin-off founded in 2006 by Dr. Jordi Mestres, coordinator of the Systems Pharmacology research group at IMIM. Chemotargets is a company that offers state-of-the-art methodologies with predictive capabilities that allow the pharmaceutical and biotechnology industry to accelerate the design and optimization of drug candidates and improve cost efficiency and safety. Its CLARITY® platform covers the entire field of drug discovery and development, from the de novo design of molecules for new targets to pharmacovigilance in the drug market stage.
25/06/2020 - General information
Dr. Ferran Sanz, Dra. Laura Furlong and Dr. Baldo Oliva of the IMIM Biomedical Informatics Research Program, participate in the Disc4All project: Training network to advance integrated computational simulations in translational medicine, applied to intervertebral disc degeneration, coordinated by Jérôme Noailly, principal investigator in the Biomechanics and Mechanobiology research area at BCN MedTech of UPF. It is one of the ten selected projects in Catalonia as an Innovative Training Network (ITN) Marie Sklodowska-Curie, in the European Commission's ITN MSC Actions call. The European innovative training networks (ITN) aim to train a new generation of researchers in their early stages who are creative, enterprising and innovative, capable of dealing with the challenges of the future and turn knowledge and ideas into products and services with an economic and a social benefit.
16/06/2020 - General information
A study conducted by researchers from the Hospital del Mar Medical Research Institute (IMIM) and the Affinity Foundation Chair at the UAB has concluded that companion animals have been an important source of emotional support for people during confinement. This benefit was greater the more the person has suffered from the confinement. The study also found that lockdown can have negative consequences for the animals. Specifically, dogs have shown more signs of nervousness and frustration, and may have trouble adjusting to their usual routine after confinement. Cats may have been exposed to excessive handling by the people they live with, which can lead to stress and adaptation problems. In short, as people we still do not really understand the language of our animals, and we have not translated their real needs adequately.
10/06/2020 - General information
The Director of the Addictions Process Group within the Institute of Neuropsychiatry and Addictions at the Hospital del Mar (INAD) and a researcher at the Hospital del Mar Medical Research Institute (IMIM) has participated in the drafting of this document, which analyses the different treatments and establishes the standards of use for the entire world. The guide was presented in March at the 63rd session of the Commission on Narcotic Drugs 2020, held at the United Nations Office in Vienna. In March, the United Nations, through its Office on Drugs and Crime (UNODC), and the World Health Organisation (WHO), jointly approved the first International standards for the treatment of drug use disorders. This document was written with the assistance of leading experts in this field, including Dr. Marta Torrens, Director of the Addictions Process Group at INAD and coordinator of the Addictions Research Group at the Hospital del Mar Medical Research Institute (IMIM). Dr. Torrens is the only author from Spain.
27/05/2020 - General information
The Spanish Transplant Society has awarded the SET 2020 grant to intensify the research activity of Dr. María José Pérez Sáez, a consultant in the Nephrology Service and a researcher at the Hospital del Mar Medical Research Institute (IMIM). It is the only grant of this type that the organisation will award this year. The 30,000 euro grant will enable Dr. Pérez Sáez to work on one of the research projects currently underway in the department and IMIM, looking at fragility in the kidney transplant waiting list. The study of fragility in candidates for kidney transplants was launched by the Hospital del Mar's Nephrology Service in 2016, and currently has data from more than 500 patients. After an initial observational phase, in which the data collected will be analysed prospectively, two more phases have been designed: to biochemically characterise the fragile patient's phenotype, for which a biobank of samples has been set up; and a final intervention phase, with a pre-habilitation clinical trial in these patients while they are awaiting a transplant.
Més informació "Grant from the Spanish Transplant Society for a study by the Nephrology Service"
Anna Bigas, CIBER Cancer (CIBERONC) researcher at the Hospital del Mar Medical Research Institute (IMIM), was appointed the new Scientific Director of CIBERONC at the CIBER Standing Committee meeting held on March 26th. Anna Bigas takes over from Joaquín Arribas, who has held this position since CIBERONC was set up in 2016. The new Scientific Director, who has already been involved in coordinating two CIBERONC programmes, Mechanisms of Tumour Progression and Training and Mobility, is the second woman to head up one of CIBER's thematic scientific areas, after the appointment of Marina Pollán as director of CIBER Epidemiology and Public Health. Dr. Bigas highlighted "the enormous scientific potential of the groups comprising CIBERONC to collaboratively address major challenges in oncology, as has already been demonstrated on several occasions. At such a critical time as the present, we need to make even more effort to unite all possible human and economic efforts to progress in the fight against cancer. In this sense, CIBERONC is able to provide unique and valuable support, making this advance a reality".
Més informació "Anna Bigas, new scientific director of CIBER Cancer"
22/01/2020 - General information
On January 10th, Jordi Mestres was officially appointed a member of the Scientific Council of ChemBioFrance, a French national research infrastructure dedicated to discovering small biologically active molecules that brings together four different sources of information: the national molecule collection (Chimiothèque Nationale); a network of screening platforms; a chemoinformatics platform; and a network of platforms for evaluating the metabolism and safety of molecules. The Scientific Council provides the infrastructure with external expertise and advice on its activity and operation. It meets once a year and comprises 9 independent scientists, experts from the various platforms, including Jordi Mestres, coordinator of the Systems Pharmacology research group at the GRIB (IMIM-UPF).
Més informació "Jordi Mestres appointed member of ChemBioFrance Scientific Council"
09/05/2019 - General information
The GRIB Integrative Biomedical Informatics group (IMIM-UPF) has launched a new version of DisGeNET, a public knowledge management platform on the genomics of disease, which is celebrating its tenth anniversary this year. DisGeNET offers information on genes and genomic variants associated with human diseases, which is obtained by integrating more than a dozen public resources and the scientific literature. DisGeNET contains one of the most comprehensive collections of genes and variants associated with human diseases that is currently available. The new version of DisGeNET (6.0) contains approximately 600,000 associations between more than 17,000 genes and 24,000 human diseases, focusing particularly on genetic alterations associated with disease: this version includes more than 117,000 genomic variants associated with 10,000 diseases. In addition, the phenotypic landscape covered by DisGeNET has been expanded to include the genomic basis of clinical manifestations of diseases, both signs and symptoms, as well as laboratory tests results.
Més informació "New version of DisGeNET 6.0 and ELIXIR recognition"
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
